



The Indonesian Journal of General Medicine

A Comprehensive Literature Review of Histopathology of Hepatocellular Carcinoma

¹ Wahyu Agus Prastyo, ¹ Artha Investari Nugraheni

¹ Faculty of Medicine, Sultan Agung Islamic University, Semarang City,
Central Java, Indonesia


Correspondence : wapyoyok@gmail.com

Article History :

Received date : 2024/09/11
Revised date : 2024/10/07
Accepted date : 2024/11/01
Published date : 2024/12/22



Copyright: © 2024 by the
authors. Submitted for possible
open access publication under
the terms and conditions of the
Creative Commons Attribution
(BY NC) license
(<https://creativecommons.org/licenses/by-nc/4.0/>).



ABSTRACT

Background: The literature surrounding hepatocellular carcinoma (HCC) reveals a complex interplay of histopathological features, molecular genetics, and clinical implications that shape the understanding and management of this prevalent malignancy. **Literature Review:** The molecular and genetic markers associated with HCC are explored by (El-Nakeep, 2022), who address the high mortality rates associated with HCC and the complex relationship between cirrhosis and HCC development. This discussion emphasizes the necessity for further investigation into the molecular pathways underlying HCC progression. The role of imaging in diagnosis and management is reinforced by (Chartampilas et al., 2022), highlighting the importance of dynamic imaging techniques in accurately staging HCC and assessing treatment responses. Moreover, localized studies, such as that by (Sweed et al., 2022), contribute to the understanding of HCC's heterogeneous nature, emphasizing morpho-molecular classifications that guide diagnosis and treatment. The immune landscape, as discussed by (Gryziak et al., 2022), introduces the implications of immune cell interactions within the tumor microenvironment, suggesting that immune profiles should be considered alongside histopathological features in tailoring treatment strategies. The mutational landscape of HCC and the potential for precision medicine are examined by (Gorji et al., 2023), advocating for personalized therapeutic strategies that account for the genetic diversity of HCC. Finally, (Hyuk Choi & N. Thung, 2023) synthesize recent advancements in histological and molecular classification, emphasizing the importance of accurate pathological classification for effective management and prognostication. **Conclusion:** In conclusion, the literature collectively underscores the critical integration of histopathological analysis with molecular insights and clinical practices to enhance the understanding of HCC. This multifaceted approach is essential for improving diagnosis, treatment, and patient outcomes in the context of this complex malignancy.

Keyword: Histopathology, Hepatocellular Carcinoma

INTRODUCTION

The literature surrounding hepatocellular carcinoma (HCC) reveals a complex interplay of histopathological features, molecular genetics, and clinical implications that shape the understanding and management of this prevalent malignancy. (A. D'Alessandro et al., 2013) provide a foundational perspective by emphasizing the multifactorial origins of HCC, particularly the roles of Hepatitis B and C viruses, as well as non-alcoholic fatty liver diseases. They highlight the progression from chronic inflammation to dysplastic changes, which are critical in defining the stages of HCC and its inherent heterogeneity, ultimately underscoring the challenges posed by genomic variability in treatment efficacy.

(Rastogi, 2018) builds upon this understanding by discussing the evolving role of histopathology in diagnosing and managing HCC. The article stresses the necessity of liver biopsy in certain contexts where imaging fails to provide definitive diagnoses, particularly in detecting small or atypical HCC variants. The

integration of tissue biomarkers and morphological features into clinical decision-making reflects an ongoing effort to refine prognostic assessments and therapeutic strategies, emphasizing the importance of histopathological insights in the clinical landscape.

(Quaglia, 2018) further elucidates the diagnostic challenges faced by pathologists in identifying HCC, particularly in patients with advanced chronic liver disease. The article discusses the potential for early prelesional signs to indicate HCC development, even in non-cirrhotic livers. This highlights the need for pathologists to be vigilant in interpreting histological changes, as the classification of HCC based on molecular and histological features can significantly influence treatment outcomes.

(El-Nakeep, 2022) contributes to the discourse by exploring the molecular and genetic markers associated with HCC, particularly the implications of bioinformatics in understanding the disease's pathogenesis. The article addresses the high mortality rates associated

with HCC and the complex relationship between cirrhosis and HCC development, calling attention to the need for further investigation into the molecular pathways that underlie HCC progression.

(Chartampilas et al., 2022) emphasize the critical role of imaging in the diagnosis and management of HCC, noting that most cases arise in patients with underlying liver disease. Their findings highlight the importance of dynamic imaging techniques in accurately staging HCC and assessing treatment responses, reinforcing the necessity of integrating imaging data with histopathological evaluation for comprehensive patient management.

(Sweed et al., 2022) offer a localized perspective by examining the clinicopathological factors of HCC in a tertiary center in Egypt. Their findings contribute to the understanding of HCC's heterogeneous nature and the importance of morpho-molecular classifications in guiding diagnosis and treatment, thereby enhancing the relevance of histopathological analysis in diverse clinical settings.

(Gryziak et al., 2022) delve into the immune landscape of HCC, discussing the implications of immune cell interactions within the tumor microenvironment. This emerging focus on immunological factors underscores the necessity of considering immune profiles alongside histopathological features in tailoring treatment strategies for HCC patients.

(Gorji et al., 2023) expand the conversation to include the mutational landscape of HCC and the potential for precision medicine. They argue for the development of personalized therapeutic strategies that take into account the genetic diversity of HCC, thereby reinforcing the need for histopathological insights to inform treatment decisions.

Finally, (Hyuk Choi & N. Thung, 2023) synthesize recent advancements in the histological and molecular classification of HCC. They highlight the importance of accurate pathological classification in managing HCC, particularly given its diverse histological subtypes and the implications for patient prognosis. Their review underscores the ongoing

challenges in diagnosing HCC and the critical role that histopathology plays in navigating these complexities.

Together, these articles reflect a comprehensive and evolving understanding of HCC, emphasizing the integration of histopathological analysis with molecular insights and clinical practices to improve diagnosis, treatment, and patient outcomes.

LITERATURE REVIEW

The article "Hepatocellular carcinoma: a systems biology perspective" by (A. D'Alessandro et al., 2013) provides a comprehensive overview of hepatocellular carcinoma (HCC), emphasizing its prevalence and the underlying biological mechanisms contributing to its development. The authors highlight that HCC is particularly common in developing countries, with major risk factors including Hepatitis B-virus (HBV) and Hepatitis C-virus (HCV) infections, as well as alcoholic and non-alcoholic fatty liver diseases. This contextual framework sets the stage for understanding the complex pathogenesis of HCC.

A critical aspect of the article is its discussion on the progression

from chronic liver inflammation to HCC, particularly through the processes of fibrosis and cirrhosis. The authors detail how these conditions lead to the expansion of dysplastic clonal hepatocyte populations, which are pivotal in the carcinogenic process. The characterization of dysplasia into low-grade and high-grade dysplastic nodules is particularly insightful, as it elucidates the morphological and biological transitions that occur prior to the development of invasive cancer. The identification of high-grade dysplastic nodules as preneoplastic lesions underscores the importance of early detection and intervention in HCC management.

Moreover, the article addresses the heterogeneity of HCC, noting that primary HCC satellite nodules exhibit varying genomic profiles. This genomic diversity is a significant factor contributing to the challenges in treatment, as it can lead to multidrug resistance and complicate the efficacy of chemotherapy. The authors argue that while liver transplantation and partial hepatectomy remain the most effective treatment options, the

limited success of chemotherapy in HCC patients highlights the need for more tailored therapeutic approaches that consider the tumor's genetic landscape.

The article "Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma" by (Rastogi, 2018) provides a comprehensive overview of the evolving significance of histopathology in the context of hepatocellular carcinoma (HCC). As one of the most prevalent and lethal cancers globally, HCC poses significant challenges due to its late presentation, high recurrence rates, and limited treatment options, which collectively contribute to a dismal prognosis. The article underscores the urgent need for advancements in both diagnosis and management strategies for HCC.

Rastogi emphasizes the critical role of liver biopsy in the diagnostic process, particularly in instances where imaging techniques may fall short. The limitations of imaging modalities in accurately identifying small lesions or atypical variants of HCC necessitate

histopathological examination to confirm diagnoses. This point is particularly salient in the context of clinical trials, where biopsy confirmation is often a prerequisite for patient enrollment in studies evaluating new therapeutic agents and targeted therapies.

The article further explores the integration of tissue analysis with clinical practice, highlighting that histopathological features, alongside tissue biomarkers, are essential for prognostic assessments and predicting treatment outcomes. The author notes that the morphological characteristics of HCC, combined with immune-phenotypic evaluations, provide a richer understanding of the tumor's behavior and potential response to therapy. This multifaceted approach is critical, especially given the molecular heterogeneity of HCC, which can significantly influence patient management.

Advancements in cancer biology are also discussed, particularly the development of molecular classifications that have led to the identification of phenotypic surrogates for prognostic and

therapeutically relevant molecular signatures. Rastogi argues that these insights are invaluable, as they inform both the clinical management of HCC and the stratification of patients for targeted therapies. The interplay between histopathology and molecular diagnostics represents a paradigm shift in how HCC is understood and treated, emphasizing the importance of integrating histological and molecular data to enhance patient outcomes.

The article "Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist" by (Quaglia, 2018) provides an in-depth exploration of the histopathological challenges faced in diagnosing hepatocellular carcinoma (HCC). Quaglia emphasizes the importance of employing additional histochemical and immunohistochemical stains, as well as conducting extensive sampling at the tumor periphery. This approach is crucial for minimizing the risk of missing vascular invasion and accurately identifying vascular remnants, which are pivotal in understanding the tumor's behavior and potential metastasis.

One of the significant insights from the article is the multifactorial nature of HCC risk in patients with advanced chronic liver disease. Factors such as gender and the underlying etiology of liver disease play critical roles in HCC development. The article also highlights the potential for small cell and large cell changes to serve as early prelesional markers for HCC, suggesting that pathologists should remain vigilant for these changes during histopathological evaluations.

Quaglia discusses the intriguing aspect of HCC occurrence in livers that are not affected by advanced chronic liver disease, indicating that HCC can develop at any age. This point underscores the necessity for pathologists to consider HCC in a broader context, particularly in patients with chronic liver conditions exhibiting severe fibrosis. The author raises an essential question regarding whether HCC may represent an anticipated progression to cirrhosis in such patients, which could influence clinical management and surveillance strategies.

The article further identifies common associated factors for HCC,

including hepatitis B virus infection, nonalcoholic steatohepatitis, genetic hemochromatosis, and exposure to environmental toxins. These associations provide a framework for pathologists to consider in their diagnostic processes, reinforcing the need for a comprehensive patient history alongside histopathological examination.

Quaglia also categorizes surgically resected HCC into two main types based on the correlation of histological and molecular features. The first category comprises large, well-differentiated cholestatic tumors characterized by mutations in CTNNB1, while the second category consists of poorly differentiated tumors with TP53 mutations. This classification not only aids in understanding the biological behavior of HCC but also has implications for therapeutic strategies and prognostication.

The article by (El-Nakeep, 2022) provides a comprehensive overview of hepatocellular carcinoma (HCC), emphasizing its significance as the most prevalent primary liver cancer and its association with

various risk factors. The author highlights the geographical prevalence of chronic hepatitis B and C, aflatoxins, and alcoholism as major contributors to HCC incidence. This contextualization is critical, as understanding the epidemiological landscape can inform targeted prevention and intervention strategies.

El-Nakeep notes the alarming statistics surrounding HCC, including an annual mortality rate exceeding 700,000 cases and a dismal 5-year survival rate of less than 50%. This underscores the urgency for advancements in both early detection and treatment modalities. The article also addresses the progression from cirrhosis to HCC, stating that 5%-30% of cirrhotic patients may develop HCC within an average of five years. This information is pivotal for clinicians, as it highlights the need for vigilant monitoring of patients with cirrhosis.

The discussion surrounding the incidence of HCC in patients treated with direct-acting antivirals (DAAs) for hepatitis C is particularly noteworthy. El-Nakeep presents a

nuanced perspective, indicating that while there has been concern regarding the potential for increased HCC rates post-treatment, recent studies suggest that the risk of both de novo and recurrent HCC is lower in patients receiving DAAs compared to those who do not. This finding is significant, as it can alleviate concerns among healthcare providers and patients regarding the safety of DAAs.

Furthermore, the article delves into the molecular and genetic markers associated with HCC, highlighting the role of bioinformatics in elucidating the molecular pathways implicated in the disease. The findings from The Cancer Genome Atlas Research Network, which identified critical pathways related to cell proliferation, differentiation, growth, apoptosis, and immortalization, are particularly relevant for future research and therapeutic development. This focus on molecular mechanisms not only enhances our understanding of HCC pathogenesis but also opens avenues for targeted therapies that could improve patient outcomes.

The article "Current Imaging Diagnosis of Hepatocellular Carcinoma" by (Chartampilas et al., 2022) provides a comprehensive overview of the role of imaging in the diagnosis and management of hepatocellular carcinoma (HCC), which is recognized as the most prevalent primary liver tumor, accounting for 75–85% of cases. The authors emphasize the alarming global incidence and mortality rates associated with HCC, particularly highlighting that men are disproportionately affected compared to women, with incidence and mortality rates being 2–3 times higher in the male population.

A critical aspect of the article is its discussion on the shifting etiology of HCC, primarily attributed to the rising prevalence of metabolic syndrome, while also acknowledging the significant contributions of hepatitis B and C infections, which account for 56% and 20% of global HCC mortality, respectively. This shift underscores the necessity for vigilant surveillance in populations at risk, particularly those with cirrhosis and chronic hepatitis B infection, to facilitate early detection of the tumor.

The authors delve into the various imaging modalities utilized in the surveillance, diagnosis, and staging of HCC. They assert that ultrasound remains a cost-effective surveillance tool that enhances survival rates, aligning with major practice guidelines. The discussion on dynamic contrast-enhanced Computed Tomography (CT) highlights its ability to exploit hemodynamic changes in cirrhotic nodules as they transition to early HCC. The characterization of suspicious nodules based on imaging findings is critical for guiding management decisions, showcasing the article's focus on the practical applications of imaging in clinical settings.

Moreover, the article introduces Magnetic Resonance Imaging (MRI) as a valuable tool that offers additional insights into nodule characteristics, such as cellularity and fat content. The incorporation of hepatospecific contrast media is noted to significantly improve the diagnostic accuracy of MRI, which is particularly relevant for differentiating HCC from other hepatic lesions. The authors

effectively illustrate the hallmark imaging features of HCC, including tumor hypervascularity during the arterial phase and hypoperfusion in the portal phase, which are essential for diagnosis.

Furthermore, the article addresses the prognostic implications of imaging findings, suggesting that the imaging appearance of HCC can yield critical information regarding disease staging, including the identification of satellite lesions, portal vein invasion, and extrahepatic metastases. This aspect of the article underscores the multifaceted role of imaging not only in diagnosis but also in assessing treatment response post-therapy, particularly given that HCC is primarily supplied by the hepatic artery.

The article "The clinicopathological and prognostic factors of hepatocellular carcinoma: a 10-year tertiary center experience in Egypt" by (Sweed et al., 2022) provides a comprehensive examination of hepatocellular carcinoma (HCC), emphasizing the disease's complexity and the need for updated classifications to aid in

diagnosis and treatment. The authors highlight that HCC presents a significant health challenge, despite advancements in preventive and therapeutic strategies.

One of the key insights from the study is the heterogeneity of HCC, which is characterized by diverse morpho-molecular patterns. This variability leads to distinct clinical manifestations and prognostic outcomes, underscoring the necessity for a nuanced understanding of the disease. The authors systematically analyze clinical and pathological data collected over a decade at a tertiary center in Egypt, aiming to refine the morpho-molecular classifications of HCC. This approach is critical, as it not only enhances diagnostic accuracy but also informs treatment decisions tailored to individual patient profiles.

The study's findings reveal various clinicopathological factors that significantly influence the prognosis of HCC patients. For instance, the authors discuss the correlation between tumor characteristics, such as size and vascular invasion, and patient

outcomes. These associations are vital for clinicians as they navigate treatment options and prognostication. Furthermore, the research underscores the importance of integrating both clinical and pathological data to form a comprehensive understanding of HCC, which can ultimately lead to improved management strategies.

In critiquing the material, it is essential to note that while the study provides valuable insights into the clinicopathological landscape of HCC, the findings are drawn from a specific geographical context. This may limit the generalizability of the results to other populations with different epidemiological profiles. Additionally, the study could benefit from a more extensive discussion on the implications of its findings for future research directions and clinical practice.

The article "The immune landscape of hepatocellular carcinoma-where we are?" by (Gryziak et al., 2022) provides an insightful overview of the role of immune cells in the tumor microenvironment of hepatocellular

carcinoma (HCC). The authors emphasize the significance of understanding the immune landscape as it pertains to the evolving treatment strategies for advanced HCC. This is particularly relevant given the increasing complexity of treatment modalities and the necessity for personalized medicine approaches in oncology.

A critical evaluation of the material reveals that the authors effectively summarize the current knowledge regarding various immune cell types present within the HCC microenvironment, highlighting their interactions and implications for tumor progression and therapy. The review underscores the importance of identifying predictive factors that can inform treatment decisions, which is crucial for optimizing therapeutic outcomes in patients with HCC. The authors argue that a better understanding of the immune microenvironment may lead to the development of tailored therapies that consider individual patient characteristics and tumor biology.

Furthermore, the article discusses the dynamic nature of

immune responses in HCC, suggesting that the immune landscape is not static but rather influenced by various factors, including tumor progression and treatment interventions. This notion is vital as it indicates that therapeutic strategies must adapt to the changing immune environment, which can impact the efficacy of treatments such as immunotherapy.

However, while the article provides a comprehensive overview of the immune landscape in HCC, it could benefit from a more detailed exploration of specific immune cell types and their distinct roles in tumorigenesis and treatment response. For instance, a deeper analysis of the mechanisms by which regulatory T cells, macrophages, and dendritic cells influence HCC progression and response to therapy would enhance the understanding of their contributions to the disease.

The article "Mutational Landscape and Precision Medicine in Hepatocellular Carcinoma" by (Gorji et al., 2023) provides a comprehensive overview of the underlying mechanisms and

complexities associated with hepatocellular carcinoma (HCC), particularly emphasizing the mutational landscape and the potential for precision medicine to enhance treatment outcomes. The authors highlight that HCC often presents as a clinically indolent disease, with diagnoses typically occurring at more advanced stages, underscoring the challenges in early detection.

A critical aspect of the article is its detailed examination of the risk factors associated with HCC development, which include viral hepatitis, alcohol-induced liver disease, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). The authors elucidate the distinct mechanisms of tumor carcinogenesis linked to viral etiologies, noting that hepatitis B virus (HBV) can integrate into host chromosomes while hepatitis C virus (HCV) does not. This distinction is crucial as it informs the understanding of how persistent inflammation and immune dysregulation contribute to HCC development.

Moreover, the role of DNA methylation in HCC pathogenesis is thoroughly discussed. The authors connect methylation processes to gene silencing, particularly in the context of NASH, where it affects key metabolic pathways and tumor suppressor genes. This molecular insight is vital for comprehending the progression from hepatic injury to malignancy, as it links epigenetic changes to the clinical manifestations of HCC.

The article also addresses the advancements in systemic therapies for HCC, acknowledging that while improvements have been made, survival rates remain suboptimal. The introduction of precision medicine as a potential solution is particularly noteworthy. The authors advocate for a personalized therapeutic approach that considers the heterogeneity of HCC and individual patient characteristics. This paradigm aims to optimize treatment strategies, although the article candidly points out the current absence of reliable biomarkers for diagnosing malignancy or predicting prognosis.

The article "Advances in Histological and Molecular Classification of Hepatocellular Carcinoma" by (Hyuk Choi & N. Thung, 2023) provides a comprehensive overview of the evolving landscape of hepatocellular carcinoma (HCC) pathology, emphasizing its molecular heterogeneity and the importance of precise diagnostic approaches. The authors highlight that HCC, a primary liver cancer, exhibits significant morphological and phenotypic diversity, which poses considerable challenges for pathologists in achieving accurate diagnoses.

One of the critical insights presented in the article is the molecular complexity of HCC, which has been elucidated through large-scale molecular profiling studies. These studies have revealed a spectrum of molecular genetic alterations that underpin the pathogenesis of HCC, enhancing the understanding of its histological subtypes. The authors note that the identification of distinct subtypes of HCC, each characterized by unique clinical, molecular, and histopathological features, has been

instrumental in refining the diagnostic criteria and treatment strategies for patients. This aspect is particularly pertinent given the generally poor prognosis associated with advanced stages of HCC.

The review also discusses the updated classification of HCC as outlined in the 2019 World Health Organization (WHO) classification of tumors. This classification not only clarifies the definition of HCC but also delineates it from other liver lesions, thereby aiding pathologists in making more informed diagnostic decisions. The authors argue that an accurate pathological classification is crucial for effective patient management and prognostication, underscoring the need for ongoing research and collaboration among pathologists and molecular biologists.

Moreover, the article emphasizes the significance of integrating histological findings with molecular data to enhance diagnostic accuracy. The authors advocate for a multidisciplinary approach that combines clinical, histopathological, and molecular information to improve outcomes for patients with HCC. This

perspective aligns with the growing recognition of personalized medicine in oncology, where tailored treatment

strategies are developed based on the specific molecular characteristics of the tumor.




Figure 1. Histopathological features of hepatocellular carcinoma (HCC)

CONCLUSION

The literature on hepatocellular carcinoma (HCC) presents a multifaceted landscape that intertwines histopathological features, molecular genetics, and clinical implications, all of which contribute to a nuanced understanding of this prevalent malignancy. The foundational work by (A. D'Alessandro et al., 2013) outlines the multifactorial origins of HCC, particularly emphasizing the roles of Hepatitis B and C viruses, as well as non-alcoholic fatty liver diseases. The

progression from chronic inflammation to dysplastic changes is critical in defining the stages of HCC, revealing the inherent heterogeneity of the disease and the challenges posed by genomic variability in treatment efficacy.

Building on this foundation, (Rastogi, 2018) discusses the evolving role of histopathology in the diagnosis and management of HCC. The necessity of liver biopsy in certain contexts, particularly in detecting small or atypical HCC

variants, underscores the importance of integrating histopathological insights into clinical decision-making. Furthermore, (Quaglia, 2018) elucidates the diagnostic challenges faced by pathologists, particularly in advanced chronic liver disease, highlighting the significance of early prelesional signs as indicators of HCC development.

The molecular and genetic markers associated with HCC are explored by (El-Nakeep, 2022), who address the high mortality rates associated with HCC and the complex relationship between cirrhosis and HCC development. This discussion emphasizes the necessity for further investigation into the molecular pathways underlying HCC progression. The role of imaging in diagnosis and management is reinforced by (Chartampilas et al., 2022), highlighting the importance of dynamic imaging techniques in accurately staging HCC and assessing treatment responses.

Moreover, localized studies, such as that by (Sweed et al., 2022), contribute to the understanding of HCC's heterogeneous nature,

emphasizing morpho-molecular classifications that guide diagnosis and treatment. The immune landscape, as discussed by (Gryziak et al., 2022), introduces the implications of immune cell interactions within the tumor microenvironment, suggesting that immune profiles should be considered alongside histopathological features in tailoring treatment strategies.

The mutational landscape of HCC and the potential for precision medicine are examined by (Gorji et al., 2023), advocating for personalized therapeutic strategies that account for the genetic diversity of HCC. Finally, (Hyuk Choi & N. Thung, 2023) synthesize recent advancements in histological and molecular classification, emphasizing the importance of accurate pathological classification for effective management and prognostication.

In conclusion, the literature collectively underscores the critical integration of histopathological analysis with molecular insights and clinical practices to enhance the understanding of HCC. This

multifaceted approach is essential for improving diagnosis, treatment, and patient outcomes in the context of this complex malignancy.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

1. A. D'Alessandro, L., Meyer, R., & Klingmüller, U., 2013. Hepatocellular carcinoma: a systems biology perspective. ncbi.nlm.nih.gov
2. Rastogi, A., 2018. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. ncbi.nlm.nih.gov
3. Quaglia, A., 2018. Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist. ncbi.nlm.nih.gov
4. El-Nakeep, S., 2022. Molecular and genetic markers in hepatocellular carcinoma: In silico analysis to clinical validation (current limitations and future promises). ncbi.nlm.nih.gov
5. Chartampilas, E., Rafailidis, V., Georgopoulou, V., Kalarakis, G., Hatzidakis, A., & Prassopoulos, P., 2022. Current Imaging Diagnosis of Hepatocellular Carcinoma. ncbi.nlm.nih.gov
6. Sweed, D., Sweed, E., Moaz, I., Mosbeh, A., Fayed, Y., Mohamed Abd Elhamed, S., Sweed, E., Macshut, M., Abdelsattar, S., Kilany, S., A. Saied, S., Badr, R., S. Abdallah, M., & Ehsan, N., 2022. The clinicopathological and prognostic factors of hepatocellular carcinoma: a 10-year tertiary center experience in Egypt. ncbi.nlm.nih.gov
7. Gryziak, M., Wozniak, K., Kraj, L., Rog, L., & Stec, R., 2022. The immune landscape of hepatocellular carcinoma-

- where we are?
ncbi.nlm.nih.gov
8. Gorji, L., J. Brown, Z., & M. Pawlik, T., 2023. Mutational Landscape and Precision Medicine in Hepatocellular Carcinoma. ncbi.nlm.nih.gov
9. Hyuk Choi, J. & N. Thung, S., 2023. Advances in Histological and Molecular Classification of Hepatocellular Carcinoma. ncbi.nlm.nih.gov